bispecific
No description yet: the sentence for this tag has not been written. 6 records carry it: 6 people.
6 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Ajai Chari Director of the Multiple Myeloma Program, UCSF Helen Diller Family Comprehensive Cancer Center · UCSF Helen Diller Family Comprehensive Cancer Center Led the pivotal talquetamab trial, establishing GPRC5D as the second bispecific target in myeloma. | Multiple myeloma | none | myeloma, gprc5d | ||
Catherine Thieblemont Head of Hemato-Oncology, Hôpital Saint-Louis, Paris; Professor, Université Paris Cité · Cancer Institute AP-HP Nord, Université Paris Cité Led EPCORE NHL-1, the trial that established the subcutaneous bispecific epcoritamab for relapsed large B-cell lymphoma. | Diffuse large B-cell lymphoma | none | lymphoma, lysa | ||
Michael Dickinson Lead, Aggressive Lymphoma Program, Peter MacCallum Cancer Centre and Royal Melbourne Hospital · Peter MacCallum Cancer Centre Led the pivotal glofitamab trial, establishing off-the-shelf bispecific antibodies for relapsed large B-cell lymphoma. | Diffuse large B-cell lymphoma | none | lymphoma, australia | ||
Paul Nathan Consultant Medical Oncologist, Mount Vernon Cancer Centre, London · Mount Vernon Cancer Centre Led the tebentafusp trial, the first treatment ever to extend survival in metastatic uveal melanoma. | Uveal melanoma, Melanoma | none | uveal-melanoma, uk | ||
Philippe Moreau Head of the Hematology Department, University Hospital Hôtel-Dieu, Nantes · Nantes University Hospital (CHU de Nantes) Led MajesTEC-1 and CASSIOPEIA, bringing the first bispecific antibody and daratumumab quadruplets to myeloma. | Multiple myeloma | none | myeloma, trialist | ||
Qing Zhou Chief of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital · Guangdong Provincial People's Hospital Chinese thoracic oncologist behind HARMONi-2, where the PD-1/VEGF bispecific ivonescimab beat pembrolizumab head to head. | Non-small-cell lung cancer | none | lung, china |